acute-kidney-injury
(4)
Klotho Therapeutics Raised $10 Million to Bottle a Longevity Protein. The Hard Part Is Still Human Proof
Klotho Therapeutics has a patented protein, a myth-sized ambition and a very human bottleneck: animal evidence is intriguing, but patients need manufacturing, dosing and trials - not mythology.
CardioRenal Systems, Inc.
CardioRenal Systems is a Milford, Massachusetts medical device company developing RenalPro (marketed as RenalGuard outside the US), an automated fluid-management system that prevents acute kidney injury in high-risk hospital settings. By monitoring urine output in real time and matching IV hydration in milliliter increments, the system keeps patients balanced during cardiac surgery, catheter procedures, and ICU care. RenalPro holds FDA Breakthrough Device Designation and a CE Mark, and in a 220-patient randomized UK trial cut AKI by 52% versus standard care.
Rapafusyn Pharmaceuticals
Rapafusyn Pharmaceuticals is a Baltimore-based, clinical-stage drug discovery company spun out of Johns Hopkins University. Its RapaGlue platform designs non-degrading, cell-permeable macrocyclic molecular glues that modulate hard-to-drug intracellular and transmembrane targets - drawing on a proprietary DNA-encoded library of more than 8 billion compounds and machine learning for target selection. The lead program, RAP-0001, is a selective ENT1 inhibitor advancing toward IND-enabling studies for the prevention of acute kidney injury in cardiac surgery patients, with a broader pipeline spanning oncology, immunology, and pain.
Ilya Budik
Ilya Budik is the CEO of CardioRenal Systems, a Milford, Massachusetts medical device company behind the RenalPro System (sold as RenalGuard outside the U.S.), a technology built to prevent acute kidney injury in cardiac surgery, interventional cardiology, and ICU patients. A medtech executive with roughly a decade of experience across strategy, finance, and business development, he has steered the company through FDA Breakthrough Device Designation, CE Mark approval abroad, and an FDA IDE approval clearing the way for a U.S. pivotal trial. He previously led the neurodiagnostics company NeuroQuest and worked in innovation strategy and healthcare finance.